Orziloben granted Orphan Drug Designation in the U.S. and European UnionCompany expects to report topline results from Phase 2 study in Q3 2026AMSTERDAM--(BUSINESS WIRE)--NorthSea Therapeutics B.V.
A new screening tool can identify the hidden driver of a silent killer through standard blood work, bypassing the need to ask ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results